

Resource Summary Report

Generated by [dkNET](#) on Sep 13, 2026

Rh30

RRID:CVCL_0041

Type: Cell Line

Proper Citation

RRID:CVCL_0041

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0041

Proper Citation: RRID:CVCL_0041

Description: Cell line Rh30 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Alveolar rhabdomyosarcoma

Defining Citation: [PMID:2766305](#), [PMID:3691179](#), [PMID:7536457](#), [PMID:8275086](#), [PMID:8383879](#), [PMID:8617485](#), [PMID:9802058](#), [PMID:11051265](#), [PMID:16957166](#), [PMID:17354236](#), [PMID:17471488](#), [PMID:19147553](#), [PMID:19235922](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20922763](#), [PMID:21948088](#), [PMID:22142829](#), [PMID:22460905](#), [PMID:23578105](#), [PMID:23665679](#), [PMID:23828214](#), [PMID:23882450](#), [PMID:25485619](#), [PMID:25749379](#), [PMID:25806826](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31448612](#), [PMID:31978347](#), [PMID:32758582](#), [PMID:35760101](#), [PMID:35839778](#), [PMID:36768928](#)

Comments: Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Rh30

Synonyms: RH30, RH-30, Rh-30, RH30SJ, SJRH-30, SJRH30, SJ-RH30, SJ-Rh 30, SJRH 30, SJCRH30, RC13, RMS-13, RMS 13, RMS13

Cross References: BTO:BTO_0005379, CLO:CLO_0009030, CLO:CLO_0037074, CLO:CLO_0037076, EFO:EFO_0005722, 4DN:4DNSR3QR626J, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2061, BCRC:60420, BCRJ:0344, BioGRID_ORCS_Cell_line:479, BioSample:SAMN03471424, BioSample:SAMN03473112, BioSample:SAMN03473563, BioSample:SAMN10987899, BioSample:SAMN10988045, cancercellines:CVCL_0041, Cell_Model_Passport:SIDM01095, ChEMBL-Cells:ChEMBL3308364, ChEMBL-Targets:ChEMBL1075575, Cosmic:687957, Cosmic:687964, Cosmic:801758, Cosmic:909716, Cosmic:1037297, Cosmic:1048110, Cosmic:1082515, Cosmic:1097749, Cosmic:1104562, Cosmic:1108737, Cosmic:1309335, Cosmic:1509197, Cosmic:1620038, Cosmic:1718361, Cosmic:2355914, Cosmic:2820087, Cosmic-CLP:909716, DepMap:ACH-000833, DepMap:ACH-001189, DepMap:ACH-001741, DSMZ:ACC-489, DSMZCellDive:ACC-489, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS504BIZ, ENCODE:ENCBS516AAA, ENCODE:ENCBS517AAA, GDSC:909716, GEO:GSM186449, GEO:GSM186450, GEO:GSM186451, GEO:GSM186452, GEO:GSM219757, GEO:GSM887573, GEO:GSM888620, GEO:GSM888656, GEO:GSM1670425, GEO:GSM1676311, GEO:GSM1676315, GEO:GSM1701645, GEO:GSM1701649, GEO:GSM7701380, GEO:GSM7701381, IARC_TP53:356, IARC_TP53:24983, IARC_TP53:27704, IGRhCellID:SJRH30, LiGeA:CCLE_004, LINCS_HMS:50041, LINCS_LDP:LCL-1408, LINCS_LDP:LCL-1414, Pharmacodb:RH30_1312_2019, PRIDE:PXD007755, PRIDE:PXD030304, PRIDE:PXD039480, Progenetix:CVCL_0041, PubChem_Cell_line:CVCL_0041, Wikidata:Q54950341

ID: CVCL_0041

Record Creation Time: 20220427T221459+0000

Record Last Update: 20260913T005900+0000

Ratings and Alerts

No rating or validation information has been found for Rh30.

No alerts have been found for Rh30.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 173 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang Y, et al. (2026) Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. Molecular cancer therapeutics, 25(6), 881.

Kim A, et al. (2026) NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition. *Molecular cancer therapeutics*.

Ying W, et al. (2026) Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma. *JCI insight*, 11(3).

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Xu A, et al. (2026) Acyltransferase ZDHHC22 promotes N-Myc transcriptional activation to drive neuroblastoma progression and chemoresistance. *Molecular cell*, 86(10), 1945.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Kucinski J, et al. (2025) Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo. *Cell reports*, 44(7), 115923.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. *iScience*, 28(8), 113149.

Mendes EA, et al. (2025) RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma. *bioRxiv : the preprint server for biology*.

Paras KI, et al. (2025) PAX3-FOXO1 Drives Targetable Cell State-Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma. *Cancer research*, 85(23), 4718.

Imle R, et al. (2025) Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas. *Nature communications*, 16(1), 5283.

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. *Cancer immunology research*, 13(10), 1591.

Kauko O, et al. (2025) Diverse oncogenes use common mechanisms to drive growth of major forms of human cancer. *Science advances*, 11(34), eadt1798.

Luo Y, et al. (2025) MiR-1 alleviates chronic heart failure through HCN2/HCN4 axis in vitro. *Tissue & cell*, 95, 102921.

Kolekar P, et al. (2024) SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4100.

Yang F, et al. (2024) GEFT inhibits the GSDM-mediated proptosis signalling pathway, promoting the progression and drug resistance of rhabdomyosarcoma. *Cell death & disease*, 15(11), 867.

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. *Genome biology*, 25(1), 301.

Hu Y, et al. (2024) Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors. *iScience*, 27(10), 110862.

Timpanaro A, et al. (2023) Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma. *International journal of molecular sciences*, 24(3).